Vitruvias Therapeutics, Inc. of Auburn, Alabama, is recalling one lot of Thyroid Tablets, USP 30 mg after testing confirmed the tablets are superpotent — meaning they may contain more active medication than labeled. The recall was announced August 21, 2026, and published by the FDA on August 24, 2026. No adverse events have been reported. The recalled lot was distributed nationwide from January through September 2025.
What’s Being Recalled?
The recall covers one lot of Vitruvias Therapeutics Thyroid Tablets, USP 30 mg, NDC 69680-166-00, Lot 504950, expiration date September 30, 2026. Approximately 1,955 units were sold. The product is a natural preparation derived from porcine thyroid glands used to treat hypothyroidism, goiters, and thyroid cancer.
Why Was This Product Recalled?
Testing confirmed the product is potentially superpotent — meaning the tablets may deliver more active thyroid hormone than the labeled dose. Taking superpotent thyroid tablets can cause hyperthyroidism, with symptoms including weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, and heart rhythm disturbances. The elderly, pregnant women, and infants face greater risk from superpotent thyroid medication. This is the opposite defect from the July 29 levothyroxine recall, which involved subpotent tablets.
What Should You Do?
Do not stop taking your thyroid medication without first contacting your healthcare provider. If your bottle is lot 504950, contact your doctor or pharmacist for a replacement prescription from an unaffected lot. Contact Vitruvias Therapeutics at 256-239-9373, Monday through Friday, 9 a.m. to 5 p.m. CT, or email [email protected].
